🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Editorial: early and persistent biological treatment and its impact on long term surgical outcomes in inflammatory bowel disease onlinelibrary.wiley.com/doi/10.1111/ap…

This is such an important message. Delays in diagnosis of #IBD increase the risk of complications including strictures & fistulae & the need for surgery. We need to improve #EarlyDiagnosis of IBD. Exceptional amount of work from Nish & SamanthaIBD #ECCO2022

🚨roypounder.apt Antidepressant (AD) use in #IBD: population-based study 🔖14k IBD & 58k control (2004-2016) 💎Among IBD pts: 📌51% increase in AD use in 12yr period 📌34% more likely to initiate AD in🥇yr after diagnosis 🤔67% AD duration less than recommended onlinelibrary.wiley.com/doi/10.1111/ap…

Fantastic to gather St George’s Hospital #IBD team together at #ECCO2023 Nish SamanthaIBD @Kpatelduracellbunny missing Dr Jonny Blackwell

"Use of opioids in IBD" by SamanthaIBD demonstrating •1 in 10 patients with IBD attending OPA were opioid exposed in the past year. •While a quarter of inpatients were discharged with opioids Access: bit.ly/46aruZY Prof Richard Pollok Christian Selinger #BSGLive23

Ulcerative colitis and the risk of 5-ASA discontinuation doi.org/10.3399/BJGP.2… Listen to the interview with Dr Nishani Jayasooriya on #UlcerativeColitis and 5-ASA NIHR ARC Northwest London NIHR SPHR NIHR Imperial BRC NIHR Applied Research Collaborations (ARCs) IBD-BOOST Crohn's & Colitis UK #PrimaryCare

SamanthaIBD Prof. Sonia Saxena 💙 Christine Norton our review of a sometimes neglected part of care for ppl c IBD Crohn's & Colitis UK IBD-BOOST

So, if you are going to be a doctor, aim for that unsolicited letter when you are old and frail. Love your patients and you will love being a doctor. 15/15

Fantastic review Prof Richard Pollok and colleagues of the management of chronic pain in #IBD fg.bmj.com/content/15/2/1…

Several stakeholders have advocated for minimising placebo controlled RCTs. We analysed the harms [Adverse Events,[AEs]] associated with placebo in inflammatory bowel diseases (IBD) RCTs. Alexander Ford Beatriz Gros Jonathan Segal Jonny Blackwell Chris Black Luminal Gastroenterology Research Leeds